Page 152 - Read Online

Dokko et al. Vessel Plus 2022;6:53 https://dx.doi.org/10.20517/2574-1209.2022.11 Page 7 of 15

Lymphoma 1.36% 1.72% 1.12% 1.00 - - - -
Chronic kidney disease 0.09 0.59
Stage 3 6.12% 10.34% 3.37% 20.00% 21.95% 18.52%
Stage 4 0.68% 1.72% 0.00% 2.11% 0.00% 3.70%
ESRD 4.76% 6.90% 3.37% 7.37% 4.88% 9.26%
CKD, with dialysis 2.04% 5.17% 0.00% 0.06 5.26% 4.88% 5.56% 1.00
CKD, without dialysis 14.97% 22.41% 10.11% 0.04 36.84% 39.02% 35.19% 0.70
Obesity 18.37% 15.52% 20.22% 0.47 29.47% 24.39% 33.33% 0.34
Iron deficiency anemia 12.93% 12.07% 13.48% 0.80 13.68% 17.07% 11.11% 0.40
Rheumatoid 5.44% 6.90% 4.49% 0.71 4.21% 2.44% 5.56% 0.63
arthritis/collagen vascular
diseases
Fluid and electrolyte 2.04% 5.17% 0.00% 0.06 1.05% 2.44% 0.00% 0.44
disorders
Pulmonary hypertension 16.33% 18.97% 14.61% 0.48 27.37% 36.59% 20.37% 0.08
Thrombocytopenia 33.33% 34.48% 32.58% 0.81 21.05% 24.39% 18.52% 0.49
Previous internal 0.68% 1.72% 0.00% 0.40 7.37% 9.76% 5.56% 0.70
cardioverter-defibrillator
Hypothyroidism 12.24% 12.07% 12.36% 0.96 15.79% 14.63% 16.67% 0.79
Intra-aortic balloon pump 2.72% 5.17% 1.12% 0.30 3.16% 2.44% 3.70% 1.00
*For categorical variables, P-values were based on chi-squared test with exact P-value from Monte Carlo simulation; for continuous variables, P-
value was based on Welch’s t-test. Note: For categorical variables, column percentages were reported; for continuous variables, mean +/- std
were reported. COPD: Chronic obstructive pulmonary disease; MI: myocardial infarction; CKD: chronic kidney disease; r-SAVR: repeat surgical
aortic valve replacements; ViV-TAVR: valve-in-valve transcatheter aortic valve replacements; POAF/AFL: postoperative atrial fibrillation/flutter.

insurance), the proportions of r_SAVR and ViV-TAVR patients in each category were quite different.
Specifically, the rates of Commercial insurance (45.6% r-SAVR versus 22.1% ViV-TAVR), Medicaid/other
insurance (4.1% r-SAVR versus 1.1% ViV-TAVR), and Medicare insurance (50.3% r-SAVR versus 76.8%
ViV-TAVR) were different (P < 0.01); thus, Medicare coverage rates appeared higher in the ViV-TAVR
patients. The ViV-TAVR patients compared to r-SAVR patients were more likely to have the following risk
factors: hypertension (85.3% vs. 73.5%, P = 0.03), congestive heart failure (49.5% vs. 18.4%, P < 0.01),
cardiomyopathy (13.7% vs. 6.1%, P = 0.05), coronary artery disease (73.7% vs. 28.6%, P < 0.01), chronic
obstructive pulmonary disease (25.3% vs. 7.5%, P < 0.01), peripheral vascular disease (9.5% vs. 2.7%,
P = 0.04), history of myocardial infarction (11.6% vs. 2.7%, P = 0.04), myocardial infarction (17.9% vs. 6.8%,
P = 0.01), dementia (5.3% vs. 0.0%, P = 0.01), hyperlipidemia (68.4% vs. 49.7%, P < 0.01), obesity (29.5% vs.
18.4%, P = 0.04), chronic kidney disease without dialysis (36.8% vs. 15.0%, P < 0.01), and pulmonary
hypertension (27.4% vs. 16.3%, P = 0.04). Furthermore, across the chronic kidney disease categories, the
proportions of ViV-TAVR patients in each category were greater (stage 3 chronic kidney disease patients:
20.0% ViV-TAVR vs. 6.1% r-SAVR; stage 4 chronic kidney disease patients: 2.1% ViV-TAVR vs. 0.7%
r-SAVR; end stage renal disease patients: 7.4% ViV-TAVR vs. 4.8% r-SAVR, P < 0.01).

Baseline characteristics of r-AVR patients with new-onset POAF/AFL
The baseline characteristics of r-AVR patients with and without POAF/AFL are compared [Table 2]. Of the
total r-AVR patients, 40.91% of patients experienced post-procedural new onset POAF/AFL. POAF/AFL
was present in 39.5% of r-SAVR patients and 43.2% of ViV-TAVR patients (P = 0.57). Patients with
POAF/AFL who underwent r-SAVR were older (mean age 69.7 ± 11.1 vs. 56.7 ± 13.2 years, P < 0.01)
compared to r-SAVR patients without POAF/AFL. Furthermore, patients with coronary artery disease
(39.7% vs. 21.4%, P = 0.02), history of acute myocardial infarction (6.9% vs. 0%, P = 0.02), and chronic
kidney disease without dialysis (22.4% vs. 10.1%, P = 0.04) were more frequent in r-SAVR patients with
POAF/AFL.